A universally applicable toolbox for single-molecule quantification of chimeric antigen receptors using linker-resolved dSTORM microscopy
Michael J, Spieler P, Toppeta F, et al.
Front Immunol. 2026 Jul 15;17:1897225.
doi: 10.3389/fimmu.2026.1897225.
Tailored strategies for improved control of CAR-T cells in multiple myeloma
Bielowski A, et al.
Front Immunol. 2026 Jan 29;17:1740345.
doi: 10.3389/fimmu.2026.1740345.
eCollection 2026.PMID: 41694366
Fine tuning towards the next generation of engineered T cells
Nguyen TT, et al.
Nat Biomed Eng. 2025 Oct;9(10):1610-1631.
doi: 10.1038/s41551-025-01492-8.
Epub 2025 Oct 10.PMID: 41073806
Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testing
Hudecek M.
Nature. 2025 Oct;646(8086):808-809.
doi: 10.1038/d41586-025-02595-7.PMID: 40993407
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
Gehrke L, et al.
Int J Mol Sci. 2024 Dec 21;25(24):13685.
doi: 10.3390/ijms252413685.
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept
Alb M, et al.
J Immunotoxicol. 2024 Oct;21(sup1):S13-S28.
doi: 10.1080/1547691X.2024.2345158.
Automated, scaled, transposon-based production of CAR T cells
Lock D, at al.
J Immunother Cancer. 2022 Sep;10(9):e005189.
doi: 10.1136/jitc-2022-005189.
Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview
Prommersberger S, et al.
Methods Mol Biol. 2022;2521:25-39.
doi: 10.1007/978-1-0716-2441-8_2.
Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer
Prommersberger S, et al.
Methods Mol Biol. 2022;2521:41-66.
doi: 10.1007/978-1-0716-2441-8_3.
The era of in vivo T cell engineering
Campos Ramos G, Hudecek M.
Med. 2022 Feb 11;3(2):85-86.
doi: 10.1016/j.medj.2022.01.012.PMID: 35590210
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
Maucher M, et al.
Cancers (Basel). 2021 Dec 7;13(24):6157.
doi: 10.3390/cancers13246157.PMID: 34944782
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Jetani H, et al.
Blood. 2021 Nov 11;138(19):1830-1842.
doi: 10.1182/blood.